{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:29:35Z","timestamp":1791833375772,"version":"4.3.4"},"reference-count":45,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Adverse outcomes associated with opioid use disorder (OUD) are disproportionately high among people with disabilities (PWD) compared with those without disability. A gap remains in understanding the quality of OUD treatment for people with physical, sensory, cognitive, and developmental disabilities, specifically regarding medications for OUD (MOUD), a foundation of treatment.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To examine the use and quality of OUD treatment in adults with diagnosed disabling conditions, compared with adults without these diagnoses.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This case-control study used Washington State Medicaid data from 2016 to 2019 (for use) and 2017 to 2018 (for continuity). Data were obtained for outpatient, residential, and inpatient settings with Medicaid claims. Participants included Washington State full-benefit Medicaid enrollees aged 18 to 64 years, continuously eligible for 12 months, with OUD during the study years and not enrolled in Medicare. Data analysis was performed from January to September 2022.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Disability status, including physical (spinal cord injury or mobility impairment), sensory (visual or hearing impairments), developmental (intellectual or developmental disability or autism), and cognitive (traumatic brain injury) disabilities.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The main outcomes were National Quality Forum\u2013endorsed quality measures: (1) use of MOUD (buprenorphine, methadone, or naltrexone) during each study year and (2) 6-month continuity of treatment (for those taking MOUD).<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 84\u202f728 Washington Medicaid enrollees had claims evidence of OUD, representing 159\u202f591 person-years (84\u202f762 person-years [53.1%] for female participants, 116\u202f145 person-years [72.8%] for non-Hispanic White participants, and 100\u202f970 person-years [63.3%] for participants aged 18-39 years); 15.5% of the population (24\u202f743 person-years) had evidence of a physical, sensory, developmental, or cognitive disability. PWD were 40% less likely than those without a disability to receive any MOUD (adjusted odds ratio [AOR],\u20090.60; 95% CI, 0.58-0.61;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). This was true for each disability type, with variations. Individuals with a developmental disability were least likely to use MOUD (AOR,\u20090.50; 95% CI, 0.46-0.55;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). Of those using MOUD, PWD were 13% less likely than people without disability to continue MOUD for 6 months (adjusted OR,\u20090.87; 95% CI, 0.82-0.93;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this case-control study of a Medicaid population, treatment differences were found between PWD and people without these disabilities; these differences cannot be explained clinically and highlight inequities in treatment. Policies and interventions to increase MOUD access are critical to reducing morbidity and mortality among PWD. Potential solutions include improved enforcement of the Americans with Disabilities Act, workforce best practice training, and addressing stigma, accessibility, and the need for accommodations to improve OUD treatment for PWD.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.2052","type":"journal-article","created":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T11:07:24Z","timestamp":1678273644000},"page":"e232052","source":"Crossref","is-referenced-by-count":26,"title":["Quality of Opioid Use Disorder Treatment for Persons With and Without Disabling Conditions"],"prefix":"10.1001","volume":"6","author":[{"given":"Cindy Parks","family":"Thomas","sequence":"first","affiliation":[{"name":"Heller School for Social Policy and Management, Brandeis University, Waltham, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen T.","family":"Stewart","sequence":"additional","affiliation":[{"name":"Heller School for Social Policy and Management, Brandeis University, Waltham, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Ledingham","sequence":"additional","affiliation":[{"name":"Heller School for Social Policy and Management, Brandeis University, Waltham, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel Sayko","family":"Adams","sequence":"additional","affiliation":[{"name":"Heller School for Social Policy and Management, Brandeis University, Waltham, Massachusetts"},{"name":"Department of Health Law, Policy and Management, Boston University School of Public Health, Boston, Massachusetts"},{"name":"Rocky Mountain Mental Illness Research Education and Clinical Center, Veterans Health Administration, Aurora, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Panas","sequence":"additional","affiliation":[{"name":"Heller School for Social Policy and Management, Brandeis University, Waltham, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Reif","sequence":"additional","affiliation":[{"name":"Heller School for Social Policy and Management, Brandeis University, Waltham, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,3,8]]},"reference":[{"issue":"2","key":"zoi230093r2","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1001\/jama.2021.7374","article-title":"Use of medications for treatment of opioid use disorder among US Medicaid enrollees in 11 states, 2014-2018.","volume":"326","author":"Donohue","year":"2021","journal-title":"JAMA"},{"key":"zoi230093r6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2020.108214","article-title":"Addressing racial & socioeconomic disparities in access to medications for opioid use disorder amid COVID-19.","volume":"122","author":"Nguemeni Tiako","year":"2021","journal-title":"J Subst Abuse Treat"},{"key":"zoi230093r7","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108710","article-title":"Growing racial\/ethnic disparities in buprenorphine distribution in the United States, 2007-2017.","volume":"223","author":"Schuler","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"zoi230093r9","doi-asserted-by":"publisher","first-page":"S198","DOI":"10.2105\/AJPH.2014.302182","article-title":"Persons with disabilities as an unrecognized health disparity population.","volume":"105","author":"Krahn","year":"2015","journal-title":"Am J Public Health"},{"issue":"2","key":"zoi230093r10","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1377\/hlthaff.2020.01452","article-title":"Physicians\u2019 perceptions of people with disability and their health care.","volume":"40","author":"Iezzoni","year":"2021","journal-title":"Health Aff (Millwood)"},{"issue":"1","key":"zoi230093r11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/00002508-200301000-00002","article-title":"Chronic pain secondary to disability: a review.","volume":"19","author":"Ehde","year":"2003","journal-title":"Clin J Pain"},{"issue":"6","key":"zoi230093r12","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1001\/jama.300.6.711","article-title":"Prevalence of chronic pain after traumatic brain injury: a systematic review.","volume":"300","author":"Nampiaparampil","year":"2008","journal-title":"JAMA"},{"key":"zoi230093r13","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s00038-009-0077-z","article-title":"Serious psychological distress among adults with and without disabilities.","volume":"54","author":"Okoro","year":"2009","journal-title":"Int J Public Health"},{"issue":"12","key":"zoi230093r14","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1377\/hlthaff.2017.0689","article-title":"Mortality quadrupled among opioid-driven hospitalizations, notably within lower-income and disabled white populations.","volume":"36","author":"Song","year":"2017","journal-title":"Health Aff (Millwood)"},{"issue":"11","key":"zoi230093r15","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.15638","article-title":"Association of disability with mortality from opioid overdose among US Medicare adults.","volume":"2","author":"Kuo","year":"2019","journal-title":"JAMA Netw Open"},{"key":"zoi230093r16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2021.106754","article-title":"Examining differences in prescription opioid use behaviors among U.S. adults with and without disabilities.","volume":"153","author":"Reif","year":"2021","journal-title":"Prev Med"},{"key":"zoi230093r17","doi-asserted-by":"publisher","DOI":"10.1016\/j.dhjo.2022.101291","article-title":"Opioid use disorder-related emergency department visits among deaf or hard of hearing adults in the United States.","volume":"15","author":"Akobirshoev","year":"2022","journal-title":"Disabil Health J"},{"issue":"5","key":"zoi230093r18","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/HTR.0000000000000730","article-title":"Traumatic brain injury and opioid use: additional evidence supporting the \u201cperfect storm\u201d of cascading vulnerabilities.","volume":"36","author":"Adams","year":"2021","journal-title":"J Head Trauma Rehabil"},{"issue":"5","key":"zoi230093r19","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1097\/HTR.0000000000000729","article-title":"Association of lifetime history of traumatic brain injury with prescription opioid use and misuse among adults.","volume":"36","author":"Adams","year":"2021","journal-title":"J Head Trauma Rehabil"},{"key":"zoi230093r21","doi-asserted-by":"publisher","DOI":"10.1016\/j.dhjo.2022.101292","article-title":"Perspectives of adults with disabilities and opioid misuse: qualitative findings illuminating experiences with stigma and substance use treatment.","volume":"15","author":"Ledingham","year":"2022","journal-title":"Disabil Health J"},{"issue":"2S","key":"zoi230093r23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/ADM.0000000000000633","article-title":"The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update.","volume":"14","author":"American Society of Addiction Medicine","year":"2020","journal-title":"J Addict Med"},{"issue":"2","key":"zoi230093r27","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/milq.2002.80.issue-2","article-title":"Using administrative data to study persons with disabilities.","volume":"80","author":"Iezzoni","year":"2002","journal-title":"Milbank Q"},{"issue":"6","key":"zoi230093r28","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1377\/hlthaff.2020.01891","article-title":"Ambulatory care access and emergency department use for Medicare beneficiaries with and without disabilities.","volume":"40","author":"Johnston","year":"2021","journal-title":"Health Aff (Millwood)"},{"issue":"1","key":"zoi230093r29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6501e1","article-title":"CDC guideline for prescribing opioids for chronic pain\u2014United States, 2016.","volume":"65","author":"Dowell","year":"2016","journal-title":"MMWR Recomm Rep"},{"key":"zoi230093r30","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jsat.2016.11.003","article-title":"Patient-reported pathways to opioid use disorders and pain-related barriers to treatment engagement.","volume":"73","author":"Stumbo","year":"2017","journal-title":"J Subst Abuse Treat"},{"issue":"10","key":"zoi230093r31","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1377\/hlthaff.2022.00475","article-title":"\u2018I am not the doctor for you\u2019: physicians\u2019 attitudes about caring for people with disabilities.","volume":"41","author":"Lagu","year":"2022","journal-title":"Health Aff (Millwood)"},{"issue":"10","key":"zoi230093r32","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1377\/hlthaff.2011.0613","article-title":"Eliminating health and health care disparities among the growing population of people with disabilities.","volume":"30","author":"Iezzoni","year":"2011","journal-title":"Health Aff (Millwood)"},{"issue":"1","key":"zoi230093r34","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1089\/neu.2019.6451","article-title":"Opioid use among individuals with traumatic brain injury: a perfect storm?","volume":"37","author":"Adams","year":"2020","journal-title":"J Neurotrauma"},{"issue":"1","key":"zoi230093r36","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1377\/hlthaff.2021.01136","article-title":"US physicians\u2019 knowledge about the Americans With Disabilities Act and accommodation of patients with disability.","volume":"41","author":"Iezzoni","year":"2022","journal-title":"Health Aff (Millwood)"},{"issue":"1","key":"zoi230093r37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jsat.2006.11.001","article-title":"The accessibility of substance abuse treatment facilities in the United States for persons with disabilities.","volume":"33","author":"West","year":"2007","journal-title":"J Subst Abuse Treat"},{"issue":"10","key":"zoi230093r39","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1176\/appi.ps.201400140","article-title":"Stigma, discrimination, treatment effectiveness, and policy: public views about drug addiction and mental illness.","volume":"65","author":"Barry","year":"2014","journal-title":"Psychiatr Serv"},{"issue":"1","key":"zoi230093r40","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12961-018-0366-1","article-title":"Disability, mental health, sexual orientation and gender identity: understanding health inequity through experience and difference.","volume":"16","author":"Nakkeeran","year":"2018","journal-title":"Health Res Policy Syst"},{"issue":"2","key":"zoi230093r41","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/ADM.0000000000000555","article-title":"Defining low-threshold buprenorphine treatment.","volume":"14","author":"Jakubowski","year":"2020","journal-title":"J Addict Med"},{"issue":"12","key":"zoi230093r42","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1377\/hlthaff.2018.05134","article-title":"How is telemedicine being used in opioid and other substance use disorder treatment?","volume":"37","author":"Huskamp","year":"2018","journal-title":"Health Aff (Millwood)"},{"issue":"2","key":"zoi230093r43","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.34993","article-title":"Association of preexisting disability with severe maternal morbidity or mortality in Ontario, Canada.","volume":"4","author":"Brown","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"6","key":"zoi230093r44","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1097\/HTR.0000000000000775","article-title":"Traumatic brain injury classification variability during the Afghanistan\/Iraq conflicts: surveillance, clinical, research, and policy implications.","volume":"37","author":"Adams","year":"2022","journal-title":"J Head Trauma Rehabil"},{"key":"zoi230093r3","volume-title":"Medications for Opioid Use Disorder Save Lives","author":"National Academies of Sciences, Engineering, and Medicine","year":"2019"},{"key":"zoi230093r38","volume-title":"Oxford Research Encyclopedia of Global Public Health","author":"Reif","year":"2023"},{"key":"zoi230093r1","unstructured":"Ahmad? F, Rossen? L, Sutton? P. Provisional drug overdose death counts. National Center for Health Statistics. 2021. Accessed March 25, 2022. https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm"},{"key":"zoi230093r4","unstructured":"Volkow? N. Access to addiction services differs by race and gender. National Institute on Drug Abuse. July 16, 2019. Accessed December 2, 2021. https:\/\/www.drugabuse.gov\/about-nida\/noras-blog\/2019\/07\/access-to-addiction-services-differs-by-race-gender"},{"key":"zoi230093r5","doi-asserted-by":"crossref","unstructured":"Madras? B, Ahmad? NJ, Wen? J, Sharfstein? J; Prevention, Treatment, and Recovery Working Group of the Action Collaborative on Countering the U.S. Opioid Epidemic. Improving access to evidence-based medical treatment for opioid use disorder: strategies to address key barriers within the treatment system. April 27, 2020. Accessed December 2, 2021. https:\/\/nam.edu\/improving-access-to-evidence-based-medical-treatment-for-opioid-use-disorder-strategies-to-address-key-barriers-within-the-treatment-system\/","DOI":"10.31478\/202004b"},{"key":"zoi230093r8","unstructured":"Centers for Disease Control and Prevention. Disability impacts all of us. March 8, 2019. Accessed March 28, 2022. https:\/\/www.cdc.gov\/ncbddd\/disabilityandhealth\/infographic-disability-impacts-all.html"},{"key":"zoi230093r20","unstructured":"National Quality Forum. Continuity of pharmacotherapy for opioid use disorder. 2019. Accessed January 31, 2023. https:\/\/qpp.cms.gov\/docs\/QPP_quality_measure_specifications\/CQM-Measures\/2019_Measure_468_MIPSCQM.pdf"},{"key":"zoi230093r22","unstructured":"Substance Abuse and Mental Health Services Administration. Substance use disorder treatment for people with physical and cognitive disabilities. 2019. Accessed February 16, 2023. https:\/\/store.samhsa.gov\/sites\/default\/files\/pep19-02-00-002.pdf"},{"key":"zoi230093r24","unstructured":"Centers for Medicare & Medicaid Services. Adult health care quality measures. 2022. Accessed March 28, 2022. https:\/\/www.medicaid.gov\/medicaid\/quality-of-care\/performance-measurement\/adult-and-child-health-care-quality-measures\/adult-health-care-quality-measures\/index.html"},{"key":"zoi230093r25","unstructured":"Centers for Medicare & Medicaid Services. Reducing substance use disorders: quality measures\u2014use of pharmacotherapy for opioid use disorder (NQF 3400). 2019. Accessed January 11, 2023. https:\/\/www.medicaid.gov\/resources-for-states\/innovation-accelerator-program\/functional-areas\/quality-measurement\/reducing-substance-use-disorders-quality-measures\/index.html"},{"key":"zoi230093r26","unstructured":"US Census Bureau. How disability data are collected from the American Community Survey. November 21, 2021. Accessed June 30, 2022. https:\/\/www.census.gov\/topics\/health\/disability\/guidance\/data-collection-acs.html"},{"key":"zoi230093r33","unstructured":"Substance Abuse and Mental Health Services Administration. TIP 29: substance use disorder treatment for people with physical and cognitive disabilities. 2012. Accessed December 1, 2021. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK64881\/pdf\/Bookshelf_NBK64881.pdf"},{"key":"zoi230093r35","unstructured":"Pulrang? A. Why is accessibility still a problem? What can we do about it? Forbes. November 21, 2019. Accessed March 29, 2022. https:\/\/www.forbes.com\/sites\/andrewpulrang\/2019\/11\/21\/why-is-accessibility-still-a-problem-what-can-we-do-about-it\/"},{"key":"zoi230093r45","unstructured":"World Health Organization. ICF beginner\u2019s guide: towards a common language for functioning, disability and health. 2002. Accessed March 28, 2022. https:\/\/www.who.int\/standards\/classifications\/international-classification-of-functioning-disability-and-health"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2802125\/thomas_2023_oi_230093_1677519732.20311.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T11:07:30Z","timestamp":1678273650000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2802125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,8]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.2052","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,8]]}}}